Kyntra Bio, Inc. (KYNB)

Kinder Morgan stock has delivered a 128.5% total return over the past 5 years, and the current valuation picture is not straightforward. An intrinsic value estimate based on a Discounted Cash Flow (DCF) approach points to meaningful upside, while market-based multiples look closer to fair value.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Kinder Morgan (NYSE:KMI) and the rest of the infrastructure stocks fared in Q1.

Looking to buy KYN Stock? Get the latest KYN quote, news, earnings, forecast, price targets, and market insights. Start investing on Public.com.

Trade KYNB stock in the pre-market on Public.com from 4:00 AM to 9:30 AM ET. Track KYNB price, range, and movement before the market opens.

Kyntra Bio (KYNB 2.16%) reported higher revenue and lower operating expenses, narrowing its quarterly net loss. The company highlighted encouraging efficacy signals from its FG3246 antibody-drug conjugate program and associated PET companion, including reduction in neutropenia through design ...